Impact of the COVID-19 Pandemic on the Prevalence of HAIs and the Use of Antibiotics in an Italian University Hospital.
COVID-19
antimicrobial resistance
healthcare-associated infections
infection prevention and control
Journal
Healthcare (Basel, Switzerland)
ISSN: 2227-9032
Titre abrégé: Healthcare (Basel)
Pays: Switzerland
ID NLM: 101666525
Informations de publication
Date de publication:
23 Aug 2022
23 Aug 2022
Historique:
received:
01
08
2022
revised:
19
08
2022
accepted:
20
08
2022
entrez:
23
9
2022
pubmed:
24
9
2022
medline:
24
9
2022
Statut:
epublish
Résumé
The COVID-19 pandemic has massively affected healthcare systems globally, causing a possible reduction in attention to traditional infection prevention programs. The objective of this study was to estimate the prevalence of healthcare-associated infections (HAIs) and the use of antimicrobials in an Italian University Hospital and to investigate whether the intensification of hospital infection control measures during the COVID-19 pandemic has affected the prevalence of bacterial HAIs. A point prevalence survey was conducted according to the simplified ECDC protocol. The survey identified a local HAI prevalence of 9.0%, revealing an increase compared to pre-pandemic values (7.3%). The survey also identified an antimicrobial exposure of 40.8%, revealing a decrease in their use compared to the study carried out in the pre-pandemic era (44.6%). Among the organizational challenges experienced during the COVID-19 pandemic, despite the greater attention paid to infection prevention measures aimed at reducing SARS-CoV-2, many healthcare facilities had to contend with the controlled availability of personnel, physical space limitations and a large number of patients. Active surveillance in hospital wards and the consequent reporting by personnel specialized in infection control is fundamental for hospitals to recognize gaps in prevention and report any observed increases in HAIs.
Identifiants
pubmed: 36141209
pii: healthcare10091597
doi: 10.3390/healthcare10091597
pmc: PMC9498585
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Clin Infect Dis. 2021 Feb 16;72(4):690-693
pubmed: 32562422
Am J Infect Control. 2021 May;49(5):653-654
pubmed: 33011335
Antimicrob Resist Infect Control. 2021 Jan 6;10(1):7
pubmed: 33407833
Infect Control Hosp Epidemiol. 2011 Feb;32(2):101-14
pubmed: 21460463
Curr Infect Dis Rep. 2019 Feb 2;21(1):2
pubmed: 30710181
Healthcare (Basel). 2022 Feb 05;10(2):
pubmed: 35206921
Lancet Infect Dis. 2019 Jan;19(1):56-66
pubmed: 30409683
Antimicrob Resist Infect Control. 2021 Jun 4;10(1):87
pubmed: 34088341
J Hosp Infect. 2020 Aug;105(4):593-595
pubmed: 32590012
Perspect Medicin Chem. 2014 Aug 28;6:25-64
pubmed: 25232278
Occup Med (Lond). 2020 Mar 12;70(1):3-5
pubmed: 32107548
Antimicrob Resist Infect Control. 2021 Aug 12;10(1):119
pubmed: 34384493
Infect Control Hosp Epidemiol. 2020 May;41(5):493-498
pubmed: 32131908
Am J Infect Control. 2021 Apr;49(4):469-477
pubmed: 33157180
BMC Med. 2020 Oct 16;18(1):329
pubmed: 33066777
Int J Infect Dis. 2021 Mar;104:287-292
pubmed: 33207271
J Infect Chemother. 2020 May;26(5):429-437
pubmed: 32081645
Infect Drug Resist. 2018 Nov 15;11:2321-2333
pubmed: 30532565
Acta Biomed. 2021 Oct 01;92(S6):e2021456
pubmed: 34739476
Infect Control Hosp Epidemiol. 2022 Jan;43(1):12-25
pubmed: 34473013
Healthcare (Basel). 2022 May 05;10(5):
pubmed: 35627982
Ann Ig. 2020 Jul-Aug;32(4):357-367
pubmed: 32744294
Clin Infect Dis. 2013 Jul;57(1):85-93
pubmed: 23532476
Cureus. 2021 Nov 7;13(11):e19331
pubmed: 34909294
Am J Infect Control. 2020 Nov;48(11):1409-1411
pubmed: 32621857
P T. 2015 Apr;40(4):277-83
pubmed: 25859123
Int J Antimicrob Agents. 2021 Jan;57(1):106245
pubmed: 33253903
Clin Microbiol Infect. 2021 Dec;27(12):1772-1776
pubmed: 34111586
Infect Control Hosp Epidemiol. 2020 Aug;41(8):946-947
pubmed: 32297849